Mika Okamoto

2.5k total citations · 1 hit paper
65 papers, 2.0k citations indexed

About

Mika Okamoto is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Mika Okamoto has authored 65 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Infectious Diseases, 27 papers in Virology and 19 papers in Epidemiology. Recurrent topics in Mika Okamoto's work include HIV/AIDS drug development and treatment (27 papers), HIV Research and Treatment (27 papers) and Hepatitis C virus research (13 papers). Mika Okamoto is often cited by papers focused on HIV/AIDS drug development and treatment (27 papers), HIV Research and Treatment (27 papers) and Hepatitis C virus research (13 papers). Mika Okamoto collaborates with scholars based in Japan, India and United States. Mika Okamoto's co-authors include Masanori Baba, Osamu Nishimura, Masahiko Fujino, Naoyuki Kanzaki, Yoshio Aramaki, Hidekazu Sawada, Mitsuru Shiraishi, Yuji Iizawa, Kenji Okonogi and Kanji Meguro and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Physical Chemistry B.

In The Last Decade

Mika Okamoto

62 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1999 634 citations Masanori Baba, Mika Okamoto et al. profile →

Peers

Countries citing papers authored by Mika Okamoto

Since Specialization

Citations

This map shows the geographic impact of Mika Okamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mika Okamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mika Okamoto more than expected).

Fields of papers citing papers by Mika Okamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mika Okamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mika Okamoto. The network helps show where Mika Okamoto may publish in the future.

Co-authorship network of co-authors of Mika Okamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Mika Okamoto. A scholar is included among the top collaborators of Mika Okamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mika Okamoto. Mika Okamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genome-Wide Association Study of Age-Related Hearing Loss in CFW Mice Identifies Multiple Genes and Loci, Including Prkag2 2025 ·Journal of the Association for Research in Otolaryngology ·Oksana Polesskaya, (unknown), Riyan Cheng, (unknown), (unknown), Eric Y. Du, (unknown), (unknown), Mika Okamoto, Abraham A. Palmer, Rick A. Friedman	0
2	Sulfoquinovosyl diacylglycerol, a component of Holy Basil Ocimum tenuiflorum, inhibits the activity of the SARS-CoV-2 main protease and viral replication in vitro 2024 ·Journal of Natural Medicines ·(unknown), Masayuki Sudoh, Satoaki Onitsuka, Hiroaki Okamura, Takeshi Ishikawa, Fumito Tani, (unknown), Mikako Shirouzu, Masanori Baba, Mika Okamoto, Toshiyuki Hamada	1
3	The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro 2020 ·Antiviral Research ·Mika Okamoto, Masaaki Toyama, Masanori Baba	28
4	Successful treatment of an AIDS patient with prolonged Mycobacterium avium bacteremia, high HIV RNA, HBV infection, Kaposi's sarcoma and cytomegalovirus retinitis 2019 ·Journal of Infection and Chemotherapy ·Yoshitaka Furukawa, (unknown), Kazuto Kamikawaji, (unknown), Hiromasa Inoue, Yukie Tashiro, Mika Okamoto, Masanori Baba, Teruto Hashiguchi	4
5	Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly 2019 ·Virus Research ·Masaaki Toyama, Norikazu Sakakibara, (unknown), Mika Okamoto, Koichi Watashi, Takaji Wakita, Masaya Sugiyama, Masashi Mizokami, Masanori Ikeda, Masanori Baba	17
6	Galectin-3 is involved in HIV-1 expression through NF-κB activation and associated with Tat in latently infected cells 2018 ·Virus Research ·Mika Okamoto, (unknown), Masaaki Toyama, Masanori Baba	13
7	Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivative. 2012 ·PubMed ·Masaaki Toyama, Takayuki Hamasaki, Tomofumi Uto, (unknown), Mika Okamoto, (unknown), Masanori Baba	14
8	Fused heterocyclic amido compounds as anti-hepatitis C virus agents 2011 ·Bioorganic & Medicinal Chemistry ·Hiroshi Aoyama, Kazuyuki Sugita, Masahiko Nakamura, (unknown), (unknown), Mika Okamoto, Masanori Baba, Yuichi Hashimoto	18
9	Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives 2011 ·Biochemical and Biophysical Research Communications ·(unknown), Hiroshi Aoyama, Kazuyuki Sugita, Koichi Watashi, Takaji Wakita, Takayuki Hamasaki, Mika Okamoto, Yasuo Urata, Yuichi Hashimoto, Masanori Baba	10
10	HIV-1-infected macrophages induce astrogliosis by SDF-1α and matrix metalloproteinases 2005 ·Biochemical and Biophysical Research Communications ·Mika Okamoto, Xin Wang, Masanori Baba	16
11	Potent activation of antigen-specific T cells by antigen-loaded nanospheres 2004 ·Immunology Letters ·Xin Wang, Tomofumi Uto, Katsuaki Sato, (unknown), Takami Akagi, Mika Okamoto, Tatsuo Kaneko, Mitsuru Akashi, (unknown)	30
12	Breast Cancer Resistance Protein (BCRP/ABCG2) Induces Cellular Resistance to HIV-1 Nucleoside Reverse Transcriptase Inhibitors 2003 ·Molecular Pharmacology ·Xin Wang, Tatsuhiko Furukawa, Takao Nitanda, Mika Okamoto, Yoshikazu Sugimoto, Shin-ichi Akiyama, Masanori Baba	113
13	Suppression of cytokine production and neural cell death by the anti-inflammatory alkaloid cepharanthine: a potential agent against HIV-1 encephalopathy 2001 ·Biochemical Pharmacology ·Mika Okamoto, Minoru Ōno, Masanori Baba	43
14	Inhibition of the RNA-Dependent Transactivation and Replication of Human Immunodeficiency Virus Type 1 by a Fluoroquinoline Derivative K-37 2000 ·Virology ·Hiroshi Okamoto, Thomas P. Cujec, Mika Okamoto, B. Matija Peterlin, Masanori Baba, Takashi Okamoto	33
15	Establishment of a CCR5-Expressing T-Lymphoblastoid Cell Line Highly Susceptible to R5 HIV Type 1 2000 ·AIDS Research and Human Retroviruses ·Masanori Baba, Hiroshi Miyake, Mika Okamoto, Yuji Iizawa, Kenji Okonogi	35
16	Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: Potential approach towards prevention of viral transmission 1998 ·Journal of Medical Virology ·Tadao Hayakawa, Masaki Kawamura, Mika Okamoto, Masanori Baba, (unknown), (unknown), Takeshi Serizawa, Mitsuru Akashi	36
17	Potent Inhibition of HIV Type 1 Replication by an Antiinflammatory Alkaloid, Cepharanthine, in Chronically Infected Monocytic Cells 1998 ·AIDS Research and Human Retroviruses ·Mika Okamoto, Minoru Ōno, Masanori Baba	59
18	Inhibition of interleukin‐6‐induced human immunodeficiency virus type 1 expression by anti‐GP130 monoclonal antibody 1997 ·IUBMB Life ·Mika Okamoto, (unknown), Kimio Katsuura, (unknown)	1
19	Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells 1996 ·Antiviral Research ·Mika Okamoto, Masahiko Makino, Kazunori Yamada, (unknown), Satoshi Yuasa, Masanori Baba	12
20	N-Alkylated Nitrogen-in-the-Ring Sugars: Conformational Basis of Inhibition of Glycosidases and HIV-1 Replication 1995 ·Journal of Medicinal Chemistry ·Naoki Asano, Haruhisa Kizu, (unknown), (unknown), (unknown), Mika Okamoto, Masanori Baba	125

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact